Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q4 FY26 results · Jan–Mar 2026
Alivus Life Sciences reported revenue from operations of ₹689.12 crore (up 6.1% from Q4 FY25) and net profit of ₹162.66 crore (up 14.7% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a standalone basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 689.12 | 649.54 | +6.1% | 672.89 | +2.4% |
| Other income | 22.78 | 10.09 | +125.8% | 13.93 | +63.5% |
| Total income | 711.89 | 659.63 | +7.9% | 686.82 | +3.7% |
| Profit before tax | 215.80 | 191.29 | +12.8% | 198.39 | +8.8% |
| Net profit for the period | 162.66 | 141.87 | +14.7% | 150.26 | +8.3% |
| EPS, basic (₹) | 13.23 | 11.57 | +14.3% | 12.25 | +8.0% |
| Net margin (%) | 23.6 | 21.8 | 22.3 |
Standalone
- Filed with BSE
- 14 May 2026, 20:50 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE